Novartis CEO Calms Concerns Over Zolgensma launch
The Swiss major has posted a strong set of financials for the second quarter and Vas Narasimhan is pleased with the roll-out of Zolgensma, Mayzent and Piqray.
You may also be interested in...
Biogen said some spinal muscular atrophy patients are currently being treated with Spinraza after receiving the Novartis gene therapy – its main competitor – so it will start a study of the risk/benefit in 2021.
Zolgensma generated $160m in the third quarter, a strong launch for the gene therapy's first full quarter on the market.
Novartis’s anti-CD20 MS candidate, ofatumumab, shows promise in initial findings from the ASCLEPIOS Phase III studies, but more details are needed to show how it stacks up against Sanofi’s Aubagio, and ultimately against Roche’s Ocrevus.